moxifloxacin ophthalmic
/ Generic mfg.
- LARVOL DELTA
Home
Next
Prev
1 to 25
Of
1417
Go to page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
July 07, 2025
REAGIR II: Rose Bengal Electromagnetic Activation With Green Light for Infection Reduction II
(clinicaltrials.gov)
- P3 | N=60 | Recruiting | Sponsor: University of California, San Francisco | Trial completion date: Dec 2025 ➔ Dec 2026 | Trial primary completion date: Jul 2025 ➔ Jun 2026
Trial completion date • Trial primary completion date • Infectious Disease • Keratitis • Ocular Infections • Ocular Inflammation • Ophthalmology
July 09, 2025
Comparison of Subconjunctival Triamcinolone with Topical Prednisolone for Routine Anti-Inflammatory Prophylaxis in Manual Small Incision Cataract Surgery: A Single-Center, Randomized Controlled Trial Pilot Protocol.
(PubMed, Clin Ophthalmol)
- P=N/A | "Subconjunctival injection of triamcinolone acetonide (TA) is an effective method to prevent postoperative inflammation in phacoemulsification eyes...Intracameral moxifloxacin 0.15% is injected at the end of surgery in both groups...The objective of this study is to evaluate the safety and efficacy of a single subconjunctival TA injection compared to standard postoperative topical therapy using PA 1% in eyes undergoing MSICS. Clinicaltrials.gov: NCT05248139; Protocol issue date: August 9, 2024; Amendment number: 02."
Journal • Cataract • Inflammation • Macular Edema • Ocular Infections • Ocular Inflammation • Ophthalmology • Uveitis
July 07, 2025
REAGIR: Rose Bengal Electromagnetic Activation With Green Light for Infection Reduction
(clinicaltrials.gov)
- P3 | N=330 | Completed | Sponsor: University of California, San Francisco | Active, not recruiting ➔ Completed
Trial completion • Infectious Disease • Keratitis • Ocular Inflammation • Ophthalmology
June 27, 2025
DVS: Dropless Pars Plana Vitrectomy Study
(clinicaltrials.gov)
- P4 | N=168 | Recruiting | Sponsor: Massachusetts Eye and Ear Infirmary | Trial completion date: Jan 2026 ➔ Jan 2027 | Trial primary completion date: Jul 2025 ➔ Jul 2026
Trial completion date • Trial primary completion date • Retinal Disorders
June 25, 2025
Development of an Effective and Cost-Saving Synergistic-Antibacterial Therapy for Prevention of Endophthalmitis.
(PubMed, Antibiotics (Basel))
- "We have found combinations of these antimicrobials that were synergistic in the total eradication (8 logs) of all bacteria tested. These three combinations were: cefuroxime/azithromycin; azithromycin/tobramycin; and cefuroxime/tobramycin. Moxifloxacin (Vigamox) did not completely eradicate Staphylococcus epidermidis. These combinations can then be used as eye drops to serve as a prophylactic for endophthalmitis after eye injections and eye surgery."
HEOR • Journal • Infectious Disease • Ocular Infections • Ocular Inflammation • Ophthalmology • Pneumonia • Respiratory Diseases
June 18, 2025
The Potential Role of Topical Losartan in Reducing Subepithelial Haze in Traumatic Laser-Assisted In Situ Keratomileusis (LASIK) Flap Avulsion.
(PubMed, Cureus)
- "A bandage contact lens was placed combined with moxifloxacin eye drops...The patient was continued on moxifloxacin four times a day (QID) and transitioned to Tobradex drops QID at day nine with improvement in UDVA to 20/30-2...Topical losartan 0.8 mg/mL was added six times per day along with fluorometholone two times a day (BID)...Uncorrected visual acuity after LASIK flap amputation is generally favorable, especially if corneal haze can be prevented. Topical losartan has anti-fibrotic activity through inhibition of the transforming growth factor-beta (TGF-β) signaling pathway, and in conjunction with topical steroids, may be effective in improving corneal haze in patients with a traumatic LASIK flap amputation."
Journal • Pain • TGFB1
June 17, 2025
Conservative management of paediatric dacryocystitis: a collection of clinical experiences highlighting effectiveness and parental satisfaction.
(PubMed, Drugs Context)
- "Patients received Crigler massages twice daily, a 0.01% hypochlorous acid-based disinfectant spray and moxifloxacin eye drops during acute episodes. The regimen was well tolerated and no surgical intervention was needed. These findings suggest that this local conservative strategy may serve as an effective first-line treatment, potentially reducing the need for invasive procedures in paediatric dacryocystitis management."
Journal • Pediatrics
June 14, 2025
Management of a complex ocular injury with endophthalmitis and corneal melting in a patient with a history of war-related trauma
(SOE 2025)
- "Despite the treatment, the patient developed corneal melting, abscesses, and persistent inflammation.Cultures revealed saprophytic flora, and the patient was intolerant of Vigamox... This case underscores the complexity of managing severe ocular trauma and infections in patients with war-related injuries, particularly those in conflict zones. Despite aggressive medical and surgical interventions, structural damage and persistent infection may require evisceration. Multidisciplinary care, tailored therapeutic strategies, and international collaboration are essential for addressing the unique challenges posed by war-related ocular trauma."
Clinical • Ocular Infections • Ocular Inflammation • Ophthalmology
May 23, 2025
Efficacy and safety of prophylactic simultaneous intravitreal moxifloxacin injection with standard intravitreal anti-VEGF injection procedure in cases of cystoid macular edema and macular neovascularization.
(PubMed, BMC Ophthalmol)
- "Simultaneous intravitreal injection of moxifloxacin during intravitreal anti-VEGF procedure is safe and effective measure to be added to the armamentarium of prophylaxis against post injection endophthalmitis."
Clinical • Journal • Macular Edema • Ocular Infections • Ocular Inflammation • Ophthalmology
March 26, 2025
A novel anterior segment imaging device for rapid, non-contact examination of conjunctival goblet cells in humans: an investigator-initiated exploratory clinical trial
(ARVO 2025)
- P=N/A | "Using fluorescence microscopy with a 0.5% moxifloxacin eye drop for labeling, the system produced images identical to PAS histology in mice, rabbits, and non-human primates...Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details."
Clinical • Ocular Inflammation • Ophthalmology
March 26, 2025
The Importance of Recognizing Blepharokeratoconjunctivitis in Children: a Case Series
(ARVO 2025)
- "She was initially treated for a right corneal ulcer and upon evaluation, in the clinic, she was diagnosed with BKC, ocular rosacea, and symptoms resolved with prednisone, moxifloxacin eyedrops, and oral azithromycin for 3 months...Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details."
Clinical • Conjunctivitis • Dry Eye Disease • Keratitis • Ocular Infections • Ocular Inflammation • Ophthalmology
March 26, 2025
Endophthalmitis After Pars Plana Vitrectomy: Safety and Efficacy of Intraoperative Intraocular Antibiotics
(ARVO 2025)
- "The impact of prophylactic intraoperative intravitreal or intracameral moxifloxacin on the development of acute infectious postoperative endophthalmitis was examined...Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details."
Clinical • Ocular Infections • Ocular Inflammation • Ophthalmology
March 26, 2025
Clinical Outcomes After Cost-Effective Dropless Cataract Surgery
(ARVO 2025)
- "Methods A retrospective chart review compared cataract surgeries using a traditional drop protocol (prednisolone acetate 1%, moxifloxacin 0.5%, ketorolac 0.5% dosed four times daily with a 4-week taper) and a dropless protocol (0.2 mL intracameral moxifloxacin 0.5% and 0.5 mL subconjunctival triamcinolone acetate 10 mg/mL). Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details."
Clinical • Clinical data • Cost effectiveness • HEOR • Surgery • Cataract • Glaucoma • Macular Edema • Ocular Infections • Ocular Inflammation • Ophthalmology
March 26, 2025
Assessment of Endothelial Cell Loss in Moxifloxacin-Treated Donor Corneal Graft Tissue
(ARVO 2025)
- "Therefore, we conducted this study to assess the safety of intracameral moxifloxacin in corneal transplantation by analyzing endothelial cell loss in donor corneal grafts...Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details."
Cataract • Ocular Infections • Ocular Inflammation • Ophthalmology
March 18, 2025
Ion-paired moxifloxacin nanocrystal formulation improves treatment and prevention of ocular infection.
(PubMed, J Control Release)
- "The sustained release functionality further led to improved or non-inferior prevention and treatment of Staphylococcus aureus-induced ocular infection in both rats and rabbits compared to gold standard intracameral moxifloxacin and moxifloxacin eye drops. By achieving therapeutically relevant moxifloxacin accumulation, this nanocrystalline moxifloxacin formulation may be a promising alternative to conventional therapies to achieve improved post-surgical infection prevention and bacterial keratitis treatment outcomes."
Journal • Cataract • Infectious Disease • Keratitis • Ocular Infections • Ocular Inflammation • Ophthalmology • Transplantation
February 24, 2025
Development of sustained-release extemporaneous moxifloxacin loaded commercial soft hydrogel contact lenses.
(PubMed, Heliyon)
- "Although moxifloxacin eye drops (0.5 % w/v) is accepted for clinical treatments of these infections, the frequent administration is challenging to achieve the adequate dose due to the limitations of low ocular bioavailability and short retention time. Furthermore, both the eye drops brands (Moximac and Zomoxin), the loading pH (6.7 and 6.0), and the loading time (24 h and 2 h) had no significant effects on the loading and release of moxifloxacin, indicating the system versatility. Conclusively, the extemporaneous moxifloxacin loaded contact lenses, with a duration of action of at least 12 h, could be further explored to become a potential treatment for eye infections."
Journal • Infectious Disease • Keratitis • Ocular Infections • Ocular Inflammation • Ophthalmology
February 03, 2025
SCUT II: Steroids and Cross-linking for Ulcer Treatment
(clinicaltrials.gov)
- P3 | N=280 | Completed | Sponsor: Thomas M. Lietman | Active, not recruiting ➔ Completed | Trial primary completion date: Aug 2024 ➔ May 2024
Trial completion • Trial primary completion date • Keratitis • Ocular Inflammation • Ophthalmology
January 23, 2025
Effects of Bromfenac on Macular Thickness After Phacoemulsification Surgery
(clinicaltrials.gov)
- P4 | N=87 | Completed | Sponsor: Inas Abd
New P4 trial • Cataract • Macular Edema • Ophthalmology
November 29, 2024
EFFICACY OF INTRACAMERAL MOXIFLOXACIN VERSUS TOPICAL MOXIFLOXACIN IN PREVENTING ACUTE ENDOPHTHALMITIS AFTER CATARACT SURGERY BY PHACOEMULSIFICATION.
(PubMed, J Ayub Med Coll Abbottabad)
- "1 ml undiluted intracameral moxifloxacin 0.5% can be given as a last step in cataract surgery by phacoemulsification to prevent postoperative acute endophthalmitis infection. This drug administration is not totally safe as our three cases developed drug reaction with moderate corneal oedema and anterior chamber reaction that resolved in a week time."
Clinical • Journal • Surgery • Cataract • Infectious Disease • Ocular Infections • Ocular Inflammation • Ophthalmology
November 15, 2024
Bilateral Corneal Endotheliitis Following Corneal Cross-linking with Riboflavin and Ultraviolet A.
(PubMed, Ann Afr Med)
- "Treatment with prednisolone acetate and moxifloxacin eye drops was initiated...In our patient, the utilization of loteprednol etabonate gel, cyclosporine eye drops, brimonidine eye drops, and regular follow-up examinations led to improved clinical findings and visual acuity. Further studies are warranted to establish optimal treatment approaches for similar cases of endotheliitis following CXL."
Journal • Achromatopsia • Ophthalmology
November 08, 2024
Study of Complication Rates in Cataract Surgery Patients Treated With Combined Pre-operative NSAID, OMIDRIA, and Subconjunctival Triamcinolone Acetonide Compared With Peri-operative SOC.
(clinicaltrials.gov)
- P1/2 | N=94 | Recruiting | Sponsor: Inder Paul Singh, M.D.
New P1/2 trial • Surgery • Cataract • Ophthalmology
October 30, 2024
REAGIR II: Rose Bengal Electromagnetic Activation With Green Light for Infection Reduction II
(clinicaltrials.gov)
- P3 | N=60 | Recruiting | Sponsor: University of California, San Francisco | Trial completion date: Jul 2025 ➔ Dec 2025 | Trial primary completion date: Dec 2024 ➔ Jul 2025
Trial completion date • Trial primary completion date • Infectious Disease • Keratitis • Ocular Infections • Ocular Inflammation • Ophthalmology
October 28, 2024
One-time low concentration betadine eye wash: A novel treatment for epidemic viral conjunctivitis for accelerated recovery.
(PubMed, Rom J Ophthalmol)
- "Group A (664 patients) underwent a 1% betadine wash in addition to the standard treatment protocol (Eye Lubricant + Moxifloxacin 0.5% eyedrops), while Group B (664 patients) followed the standard protocol alone. A single low-concentration betadine wash expedites recovery and reduces complications in acute infective conjunctivitis. This approach significantly enhances patient outcomes and alleviates the socioeconomic impact of the condition."
Journal • Conjunctivitis • Hematological Disorders • Infectious Disease • Inflammation • Keratitis • Ocular Infections • Ocular Inflammation • Ophthalmology
September 24, 2024
Intracameral Moxifloxacin Dose for POE Prophylaxis for PCR
(AAO 2024)
- "The use of dilute ICM is important to prevent drug toxicity. The precise methodology, results and cautions will be presented."
Ocular Infections • Ocular Inflammation • Ophthalmology
July 28, 2024
A Different Amniotic Membrane Transplantation Technique In Necrotizing Stromal Keratitis
(ESCRS 2024)
- "In the patient's history, he applied dexamethasone eye drops without consulting a doctor due to redness in his right eye...The patient was initiated on acyclovir tablets 5x400 mg, oral vitamin C preparate 1x1, tetracycline tablets 1x1, moxifloxacin eye drops 4x1, and tropicamide eye drops 3x1...Conclusion/Take home message: Uncontrolled topical steroid use on the background of neurotrophic keratopathy can lead to corneal melting and perforation. Amniotic membrane transplantation techniques are beneficial in the treatment."
Stroma • Cataract • Dry Eye Disease • Keratitis • Ocular Inflammation • Ophthalmology
1 to 25
Of
1417
Go to page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57